Disease Domain | Count |
---|---|
Infectious Diseases | 7 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 4 |
Vaccine | 3 |
Genetically engineered subunit vaccine | 1 |
Combination vaccine | 1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. TW |
First Approval Date17 Jul 2021 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date01 Apr 2016 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jul 2022 |
Sponsor / Collaborator |
Start Date09 Jul 2022 |
Sponsor / Collaborator |
Start Date06 May 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MVC-COV1901 ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
Enterovirus A vaccine (Adimmune/Medigen Vaccine Biologics) | Enterovirus 71 infection More | NDA/BLA |
Quadrivalent influenza virus vaccine(Green Cross Corp.) | Influenza, Human More | Phase 3 |
COVID-19 Vaccine ( Medigen) | COVID-19 More | Phase 2 |
H7N9 influenza vaccine(National Health Research Institutes) ( HER2 ) | Influenza, Human More | Phase 2 |